Understanding why some people develop antibodies to blood transfusions
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 1
This project explores why some patients develop antibodies against transfused red blood cells, especially those with autoimmune tendencies, to make transfusions safer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11134690 on NIH RePORTER |
What this research studies
When you receive a blood transfusion, your body might sometimes create antibodies against the new red blood cells, a process called alloimmunization. This can make future transfusions more difficult or even risky. We know that some people are more likely to develop these antibodies than others, particularly those with certain autoimmune conditions. This project aims to uncover the specific biological reasons behind this difference, focusing on how certain immune signals and antibodies, like those seen in conditions similar to lupus, might trigger this reaction. By understanding these mechanisms, we hope to find ways to prevent alloimmunization and improve transfusion safety for everyone.
Who could benefit from this research
Good fit: Patients who receive regular blood transfusions and those with autoimmune conditions, particularly those who have experienced or are at risk for alloimmunization, are the focus of this research.
Not a fit: Patients who do not require blood transfusions or do not have conditions that predispose them to alloimmunization may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to prevent the body from rejecting transfused blood, making transfusions safer and more effective for patients who need them regularly.
How similar studies have performed: While the general problem of alloimmunization is known, this specific approach of linking anti-nuclear antibodies and TLR signaling to responder status is a novel direction building on recent discoveries in animal models.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Jash, Arijita — University of Virginia
- Study coordinator: Jash, Arijita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.